文献速递生殖医学

基于干细胞的男性生育力恢复:从睾丸干细胞到多能干细胞体外配子发生

Male fertility restoration with stem cell-based therapies: from testicular stem cells to pluripotent stem cell-based in vitro gametogenesis.
PubMed 文献 · Fertil Steril · 2025-05-19

男性因素不育影响全球8%-12%的夫妇,现有精子冷冻保存对青春期前患者及非梗阻性无精子症患者选择有限。本综述探讨睾丸组织移植、器官培养、细胞重建、精原干细胞移植及多能干细胞体外配子发生等新兴干细胞疗法,这些方法在小鼠等动物模型中显示出显著效果,但临床转化面临科学、伦理和监管挑战。

要点

  • 男性因素不育影响全球8%-12%的夫妇。
  • 现有精子冷冻保存对青春期前及非梗阻性无精子症患者选择有限。
  • 干细胞疗法在动物模型中显示效果,但临床转化面临科学、伦理和监管挑战。

核心结论

  • 干细胞策略为恢复生育潜力提供有希望的途径,为目前无生殖选择的患者带来希望。

研究设计与样本

  • 综述,探讨睾丸组织移植、器官培养、细胞重建、精原干细胞移植及多能干细胞体外配子发生等干细胞疗法。

主要发现

  • 这些方法在动物模型(尤其小鼠)中显示出显著效果。

局限性

  • 临床转化面临显著的科学、伦理和监管挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Male factor infertility poses a substantial clinical challenge, affecting 8%-12% of couples worldwide. The underlying causes of this condition range from cancer treatments to congenital disorders. The present approach to fertility preservation entails the cryopreservation of sperm for postpubertal males. However, this method offers limited options for prepubertal patients and those with nonobstructive azoospermia. This review examines emerging stem cell-based therapies, including testicular tissue grafting, organ culture, cell reconstitution, spermatogonial stem cell transplantation, and pluripotent stem cell-derived in vitro gametogenesis. Although these approaches have demonstrated notable efficacy in animal models, particularly in mice, translating these technologies into clinical applications is confronted by significant scientific, ethical, and regulatory challenges. These innovative stem cell strategies offer promising pathways to restore fertility potential and provide hope for patients currently without reproductive options.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Hwang YS, Clark AT. Male fertility restoration with stem cell-based therapies: from testicular stem cells to pluripotent stem cell-based in vitro gametogenesis. Fertil Steril. 2025. PMID: 40398716. doi:10.1016/j.fertnstert.2025.05.145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。